N-terminally truncated IGF-1 analogue lacking residues 1–3
PRODUCT PROFILE
IGF-1 DES
£62.00
IGF-1 DES is n-terminally truncated igf-1 analogue lacking residues 1–3. Researchers examine it in relation to short-range, high-potency igf-1 receptor signalling in tissue and cell models.
Why it is distinct
A short-acting truncated analogue, contrasted with the extended long-exposure design of IGF-1 LR3.
- Evidence stageExperimental
- AvailabilityUnavailable
- Batch recordPublished after verification
- DispatchConfirmed at checkout
Out of stock
Ask about availabilityPRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
IGF-1 DES is n-terminally truncated igf-1 analogue lacking residues 1–3. Researchers examine it in relation to short-range, high-potency igf-1 receptor signalling in tissue and cell models.
Research focus+
Researchers use it to examine cell growth and repair signals over a shorter range. It is highly experimental and lacks established consumer use.
How the mechanism differs+
Reduced binding-protein affinity and preserved receptor activity produce strong local experimental signalling.
Evidence and limitations+
Preclinical research reagent with no established human therapeutic evidence.
Testing and batch documentation+
No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.
RESEARCH PROFILE
Understand the distinction.
Researchers use it to examine cell growth and repair signals over a shorter range. It is highly experimental and lacks established consumer use.
Reduced binding-protein affinity and preserved receptor activity produce strong local experimental signalling.
A short-acting truncated analogue, contrasted with the extended long-exposure design of IGF-1 LR3.
Preclinical research reagent with no established human therapeutic evidence.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Experimental
Follistatin 344
£76.001 mgBatch file pendingA ligand-binding inhibitor of the activin/myostatin system, not a GH or IGF secretagogue.
UnavailableAsk about availability -
Early human evidence
CJC-1295 No DAC
Price range: £25.99 through £32.995 mgBatch file pendingShort-duration GHRH signalling, in contrast with albumin-bound, long-acting CJC-1295 DAC.
UnavailableAsk about availability This product has multiple variants. The options may be chosen on the product page -
Established
Sermorelin
£49.005 mgBatch file pendingClosest to the natural active GHRH sequence and shorter acting than tesamorelin or CJC-1295 DAC.
UnavailableAsk about availability -
Early human evidence
Hexarelin
£51.005 mgBatch file pendingA potent older GHRP with less hormonal selectivity than ipamorelin.
UnavailableAsk about availability